UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported)
June 7, 2004
ISTA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
| | | | |
| Delaware | | 000-31255 | | 33-0511729 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
| | |
| 15279 Alton Parkway, Suite 100, Irvine, CA | | 92618 |
| (Address of principal executive offices) | | (Zip Code) |
Registrant’s telephone number, including area code: (949) 788-6000
Item 5. – Other Events and Regulation FD Disclosure
On June 7, 2004, the Registrant announced that the U.S. Food and Drug Administration approved the New Drug Application for Istalol™, a once-a-day liquid formulation of timolol, for the treatment of glaucoma. A copy of the press release containing the foregoing announcement is attached hereto as Exhibit 99.1 and is incorporated herein by reference.
Item 7. – Financial Statements and Exhibits
| | |
Exhibit Number
| | Description
|
| |
| 99.1 | | Press Release dated June 7, 2004. |
Signatures
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| | | | | | | | |
| | | | | ISTA PHARMACEUTICALS, INC. |
| | | |
| June 8, 2004 | | | | By: | | /s/ Lauren Silvernail |
| | | | | | | | | Lauren Silvernail, Chief Financial Officer, Chief Accounting Officer and Vice President, Corporate Development |
EXHIBIT INDEX
| | |
Exhibit Number
| | Description
|
| |
| 99.1 | | Press Release dated June 7, 2004. |
